ASX-listed well being tech agency CardieX introduced it acquired Silicon Valley-based Blumio, a developer of cardiovascular sensor algorithms and knowledge analytics instruments.
CardieX focuses on hypertension, cardiovascular well being and different arterial well being issues, whereas Blumio develops wearable-sensor applied sciences centered on capturing cardiovascular knowledge, together with blood stress measurements.
The acquisition follows a three-year collaboration between the businesses, which decided Blumio’s sensor know-how was appropriate with CardieX subsidiary ATCOR’s SphygmoCor arterial technology that measures the central aortic stress waveform.
CardieX can even make the most of Blumio’s property to enhance its Arty Coronary heart Well being Analytics Platform in its CONNEQT Pulse and for its CONNEQT Band units.
“Blumio brings a collection of capabilities in wearable sensor growth, sign processing and large knowledge analytics experience that can profit each of our ATCOR and CONNEQT manufacturers, particularly in relation to the continuing growth actions surrounding our CONNEQT Band. This acquisition is a pure extension of our core options that present a complete ecosystem of distinctive well being and wellness options centered on coronary heart well being,” CardieX Group CEO Craig Cooper stated in a press release.
THE LARGER TREND
CardieX provides Blumio to its group of corporations with numerous patented healthcare technologies.
In March, CardieX and AI-enabled wearable firm, Mobvoi, introduced the launch of its TicWatch GTH Pro, which leverages features of ATCOR’s coronary heart well being monitoring SphygmoCor know-how.
